Status:
COMPLETED
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Sickle Cell Disease
Renal Disease
Eligibility:
All Genders
5-50 years
Brief Summary
The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients
Detailed Description
200 pediatric and 200 adult SCA participants will undergo mGFR using iohexol at baseline and at one year. On the same day, participants will undergo clinical and laboratory variables important for dev...
Eligibility Criteria
Inclusion
- SCA patients (HbSS and SB0 thalassemia)
- Age: 5.0-50.0 at enrollment
Exclusion
- Recent SCA complication associated with hospitalization (within 30 days) or ED visit (within 14 days)
- Current AKI defined as \>0.3mg/g increase in SCr from prior visit
- Known history of anaphylaxis with contrast agent or known pregnancy
Key Trial Info
Start Date :
May 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04380610
Start Date
May 12 2021
End Date
June 30 2025
Last Update
September 18 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35223
2
University of Illinois Chicage
Chicago, Illinois, United States, 60612
3
St Jude Childrens Research Hospital
Memphis, Tennessee, United States, 38106
4
University of Tennessee Health Science Center
Memphis, Tennessee, United States, 38163